Detecting molecular abnormalities in glioma exosomes
Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes
This study is testing whether analyzing tiny particles from the blood of glioma patients can provide better information about their tumors compared to a standard test.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Limoges Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Limoges) |
| Trial ID | NCT06116903 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to evaluate the effectiveness of analyzing molecular abnormalities in exosomes derived from glioblastomas compared to the standard Foundation One Liquid CDx test. Gliomas, the most common primary brain tumors in adults, present challenges in diagnosis and management due to their heterogeneity. By utilizing next-generation sequencing (NGS) to profile circulating exosomes, the study seeks to provide more reliable and sensitive results for characterizing gliomas. Blood samples will be collected from eligible patients to assess the molecular alterations present in their tumors.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with glioblastoma who have progressed after first-line chemotherapy and radiotherapy.
Not a fit: Patients with active malignancies or those involved in other experimental protocols may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and efficient diagnosis and management of gliomas.
How similar studies have performed: While this approach is promising, it is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject of both sexes at least 18 years of age with glioblastoma. * Patient for whom an FMI test is indicated, progressing after a 1st line following the chemotherapy and radiotherapy protocol (STUPP protocol) * Patient affiliated to French social security Exclusion Criteria: * Patient included in another research protocol using an experimental molecule. * Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol * Patient under legal protection, guardianship or curatorship * Patient with active malignancy or a previous malignancy within the past 5 years; except for patient with resected Basocarcinoma and resected carcinoma in-situ of the cervix.
Where this trial is running
Limoges
- CHU de Limoges — Limoges, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.